If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What happens to weight loss and glycemic control after discontinuation of Mounjaro™ (tirzepatide)?
Lilly has no information about the changes in weight loss and glycemic control after discontinuation of tirzepatide in SURPASS studies.
See important safety information, including boxed warning, in the attached prescribing information.
Efficacy After Discontinuation
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
Eli Lilly and Company does not currently have any data about the changes in weight loss or glycemic control after tirzepatide discontinuation because this information has not been analyzed from SURPASS clinical studies.
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: February 14, 2023